Cargando…

Valproic Acid Increases CD133 Positive Cells that Show Low Sensitivity to Cytostatics in Neuroblastoma

Valproic acid (VPA) is a well-known antiepileptic drug that exhibits antitumor activities through its action as a histone deacetylase inhibitor. CD133 is considered to be a cancer stem cell marker in several tumors including neuroblastoma. CD133 transcription is strictly regulated by epigenetic modi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khalil, Mohamed Ashraf, Hraběta, Jan, Groh, Tomáš, Procházka, Pavel, Doktorová, Helena, Eckschlager, Tomáš
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023141/ https://www.ncbi.nlm.nih.gov/pubmed/27627801 http://dx.doi.org/10.1371/journal.pone.0162916

Ejemplares similares

Valproic acid overcomes hypoxia-induced resistance to apoptosis
por: CIPRO, ŠIMON, et al.
Publicado: (2011)

The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells
por: Cerna, Tereza, et al.
Publicado: (2018)

Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells
por: Hřebačková, Jana, et al.
Publicado: (2009)

The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells
por: Poljaková, Jitka, et al.
Publicado: (2008)

An Adsorptive Transfer Technique Coupled with Brdicka Reaction to Reveal the Importance of Metallothionein in Chemotherapy with Platinum Based Cytostatics
por: Krizkova, Sona, et al.
Publicado: (2010)

MIAT Is an Upstream Regulator of NMYC and the Disruption of the MIAT/NMYC Axis Induces Cell Death in NMYC Amplified Neuroblastoma Cell Lines
por: Feriancikova, Barbara, et al.
Publicado: (2021)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

DNA and histone deacetylases as targets for neuroblastoma treatment
por: Stiborová, Marie, et al.
Publicado: (2010)

Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker
por: Kruseova, Jarmila, et al.
Publicado: (2013)

Drug Sequestration in Lysosomes as One of the Mechanisms of Chemoresistance of Cancer Cells and the Possibilities of Its Inhibition
por: Hraběta, Jan, et al.
Publicado: (2020)

Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
por: Jáklová, Kateřina, et al.
Publicado: (2021)

CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure
por: Tsunekuni, Kenta, et al.
Publicado: (2019)

Ascorbate sensitizes human osteosarcoma cells to the cytostatic effects of cisplatin
por: Oka, Naohiro, et al.
Publicado: (2020)

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010)

Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines
por: Veselska, Renata, et al.
Publicado: (2008)

CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma
por: Zhong, Zhi-Yong, et al.
Publicado: (2018)

Extending the Applicability of In Ovo and Ex Ovo Chicken Chorioallantoic Membrane Assays to Study Cytostatic Activity in Neuroblastoma Cells
por: Merlos Rodrigo, Miguel Angel, et al.
Publicado: (2021)

Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines
por: Holzhauser, Stefan, et al.
Publicado: (2021)

CD133 Expression and Identification of CD133/nestin Positive Cells in Rhabdomyosarcomas and Rhabdomyosarcoma Cell Lines
por: Sana, Jiri, et al.
Publicado: (2011)

Targeting the endoplasmic reticulum-mitochondria interface sensitizes leukemia cells to cytostatics
por: Koczian, Fabian, et al.
Publicado: (2019)

Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium
por: Blaheta, R A, et al.
Publicado: (2007)

Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells
por: Stockhausen, M-T, et al.
Publicado: (2005)

Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018)

THE CD133-POSITIVE COLON CANCER CELL PHENOTYPE IS MORE INTERACTIVE WITH THE TUMOR MICROENVIRONMENT COMPARED TO CD133-NEGATIVE CELL
por: Chao, Celia, et al.
Publicado: (2011)

Metallothionein-3 promotes cisplatin chemoresistance remodelling in neuroblastoma
por: Rodrigo, Miguel Angel Merlos, et al.
Publicado: (2021)

Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations
por: Grasso, Carole, et al.
Publicado: (2016)

Intrathecal Chemotherapy: Selection of Cytostatic Agents
por: Hayakawa, T., et al.
Publicado: (1970)

The cytostatic activity of cultured Kupffer cells.
por: Pulford, K., et al.
Publicado: (1985)

The effect of valproic acid on intrinsic, extrinsic, and JAK/STAT pathways in neuroblastoma and glioblastoma cell lines
por: Sanaei, Masumeh, et al.
Publicado: (2022)

Effects of CD133 expression on chemotherapy and drug sensitivity of adenoid cystic carcinoma
por: Zhou, Lian, et al.
Publicado: (2022)

Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure
por: Fritzenwanger, M, et al.
Publicado: (2009)

Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma
por: Yamamoto, J, et al.
Publicado: (2014)

In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133(high) to CD133(low) phenotype and reduces the CD133-related invasiveness
por: Brugnoli, Federica, et al.
Publicado: (2013)

Childhood survivors of high‐risk neuroblastoma show signs of immune recovery and not immunosenescence
por: Lázničková, Petra, et al.
Publicado: (2020)

CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells
por: Barrantes-Freer, Alonso, et al.
Publicado: (2015)

CD133 antisense suppresses cancer cell growth and increases sensitivity to cisplatin in vitro
por: BLANCAS-MOSQUEDA, MARISOL, et al.
Publicado: (2012)

CD133 Role in Oral Carcinogenesis
por: Luna, Ealber Carvalho Macedo, et al.
Publicado: (2020)

Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma
por: Yu, Ji-wei, et al.
Publicado: (2010)

Signaling Mechanisms that Suppress the Cytostatic Actions of Rapamycin
por: Jahn, Stephan C., et al.
Publicado: (2014)

Optimisation of maintenance in delivery systems for cytostatic medicines
por: Carnero, María Carmen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0h14oqr9n5p17m75o6i621gn1s